Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B, Breton JL, Lemarie E, Pujol JL, Brechot JM, Zalcman G, Debieuvre D, Vaylet F, Vergnenegre A, Clouet P.
Quoix E, et al. Among authors: vergnenegre a.
Ann Oncol. 2004 Jan;15(1):38-44. doi: 10.1093/annonc/mdh005.
Ann Oncol. 2004.
PMID: 14679117
Free article.
Clinical Trial.